Aderis' novel product candidates are small molecules designed to selectively enhance (agonists) or block (antagonists) the activity of certain proteins such as receptors or enzymes. We focus on selectively activating only the receptors necessary for therapeutic benefit, which results in development of pharmaceutical drug candidates that offer more potent action and fewer side effects. For more information about Aderis and its products, click here.

Neupro™ Rotigotine (SPM-962) Parkinson's disease Dopamine Agonist 4 million WW Rotigotine (SPM-962) Restless Legs Syndrome Dopamine Agonist 12 million US Binodenoson (MRE-0470) Cardiac Diagnosis Adenosine A2A Agonist 2.4 million tests/year in US Selodenoson (DTI-0009) Atrial Fibrillation Adenosine A1 Agonist 6 million WW MRE-0094 Wound Healing in Diabetic Foot Ulcers Adenosine A2A Agonist 22 million in US CF1011 Colorectal Cancer and Rheumatoid Arthritis Adenosine A3 Agonist

For more information on a particular product candidate, please click on the corresponding product name in the chart above. [1] Licensed to Canfite BioPharma